Nicole Gastineau Campos, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uterine Cervical Neoplasms | 44 | 2024 | 2020 | 6.700 |
Why?
|
Papillomavirus Infections | 38 | 2024 | 1587 | 6.280 |
Why?
|
Uterine Cervical Dysplasia | 9 | 2022 | 387 | 3.710 |
Why?
|
Early Detection of Cancer | 25 | 2024 | 3086 | 3.330 |
Why?
|
Papillomavirus Vaccines | 16 | 2023 | 491 | 2.590 |
Why?
|
Cost-Benefit Analysis | 24 | 2021 | 5391 | 2.140 |
Why?
|
Papillomaviridae | 14 | 2023 | 1119 | 2.080 |
Why?
|
Mass Screening | 21 | 2023 | 5255 | 1.950 |
Why?
|
Alphapapillomavirus | 7 | 2022 | 221 | 1.810 |
Why?
|
Colposcopy | 9 | 2022 | 144 | 1.200 |
Why?
|
Models, Theoretical | 10 | 2019 | 3589 | 1.130 |
Why?
|
Health Resources | 4 | 2017 | 911 | 0.940 |
Why?
|
Human papillomavirus 18 | 8 | 2023 | 128 | 0.830 |
Why?
|
Human papillomavirus 16 | 9 | 2023 | 262 | 0.810 |
Why?
|
Vaccination | 10 | 2023 | 3278 | 0.780 |
Why?
|
Monte Carlo Method | 7 | 2021 | 1254 | 0.750 |
Why?
|
Health Policy | 4 | 2019 | 2661 | 0.740 |
Why?
|
Developing Countries | 10 | 2020 | 2815 | 0.680 |
Why?
|
Specimen Handling | 3 | 2021 | 694 | 0.630 |
Why?
|
Computer Simulation | 6 | 2021 | 6196 | 0.620 |
Why?
|
Models, Economic | 4 | 2021 | 713 | 0.620 |
Why?
|
Vaginal Smears | 7 | 2021 | 511 | 0.590 |
Why?
|
DNA, Viral | 4 | 2020 | 2225 | 0.540 |
Why?
|
Medically Underserved Area | 1 | 2017 | 253 | 0.510 |
Why?
|
El Salvador | 3 | 2019 | 39 | 0.480 |
Why?
|
Bioethics | 2 | 2004 | 116 | 0.430 |
Why?
|
Uganda | 6 | 2019 | 1243 | 0.410 |
Why?
|
Choice Behavior | 1 | 2017 | 803 | 0.390 |
Why?
|
Selection Bias | 1 | 2011 | 371 | 0.350 |
Why?
|
Female | 51 | 2024 | 380194 | 0.330 |
Why?
|
Mass Vaccination | 2 | 2019 | 105 | 0.300 |
Why?
|
Models, Statistical | 3 | 2017 | 5102 | 0.270 |
Why?
|
Adult | 28 | 2023 | 214055 | 0.260 |
Why?
|
Mississippi | 2 | 2021 | 88 | 0.240 |
Why?
|
Public Health | 1 | 2017 | 2603 | 0.240 |
Why?
|
Humans | 54 | 2024 | 744343 | 0.230 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2007 | 657 | 0.220 |
Why?
|
Human Experimentation | 1 | 2004 | 127 | 0.220 |
Why?
|
Cryosurgery | 2 | 2018 | 453 | 0.220 |
Why?
|
Social Justice | 2 | 2004 | 456 | 0.210 |
Why?
|
Middle Aged | 20 | 2022 | 213383 | 0.210 |
Why?
|
Costa Rica | 3 | 2023 | 177 | 0.200 |
Why?
|
Resource Allocation | 1 | 2004 | 341 | 0.200 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2017 | 4034 | 0.190 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2023 | 9959 | 0.190 |
Why?
|
Human Rights | 1 | 2004 | 307 | 0.190 |
Why?
|
Quality-Adjusted Life Years | 5 | 2019 | 1683 | 0.190 |
Why?
|
Young Adult | 9 | 2019 | 56430 | 0.160 |
Why?
|
New Mexico | 2 | 2018 | 86 | 0.160 |
Why?
|
Hepatitis C, Chronic | 1 | 2007 | 1031 | 0.160 |
Why?
|
HIV Infections | 4 | 2022 | 16718 | 0.160 |
Why?
|
Nicaragua | 1 | 2017 | 27 | 0.150 |
Why?
|
Models, Biological | 1 | 2014 | 9583 | 0.150 |
Why?
|
Decision Making | 1 | 2011 | 3887 | 0.150 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2023 | 477 | 0.150 |
Why?
|
Cost of Illness | 1 | 2007 | 1859 | 0.150 |
Why?
|
Immunization Schedule | 1 | 2018 | 221 | 0.150 |
Why?
|
Cancer Vaccines | 1 | 2023 | 1023 | 0.130 |
Why?
|
Healthcare Disparities | 2 | 2023 | 3158 | 0.130 |
Why?
|
Women's Health | 2 | 2017 | 2034 | 0.130 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 441 | 0.130 |
Why?
|
Antiviral Agents | 1 | 2007 | 2987 | 0.120 |
Why?
|
Incidence | 5 | 2023 | 20947 | 0.120 |
Why?
|
South Africa | 1 | 2018 | 1731 | 0.110 |
Why?
|
Risk Reduction Behavior | 2 | 2017 | 1125 | 0.110 |
Why?
|
Poverty | 1 | 2004 | 2660 | 0.100 |
Why?
|
India | 1 | 2018 | 2197 | 0.100 |
Why?
|
Physical Examination | 1 | 2018 | 1237 | 0.100 |
Why?
|
Colorectal Neoplasms | 3 | 2023 | 6773 | 0.100 |
Why?
|
Health Status Disparities | 1 | 2023 | 1797 | 0.100 |
Why?
|
Africa, Eastern | 1 | 2011 | 71 | 0.100 |
Why?
|
Health Promotion | 1 | 2004 | 2205 | 0.100 |
Why?
|
Sexual Behavior | 1 | 2021 | 2057 | 0.100 |
Why?
|
Guidelines as Topic | 1 | 2018 | 1405 | 0.100 |
Why?
|
Patient Compliance | 1 | 2021 | 2684 | 0.090 |
Why?
|
Life Expectancy | 1 | 2017 | 1184 | 0.090 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2015 | 602 | 0.090 |
Why?
|
Adolescent | 10 | 2021 | 85781 | 0.090 |
Why?
|
Time | 1 | 2011 | 542 | 0.090 |
Why?
|
Health Care Surveys | 1 | 2017 | 2453 | 0.090 |
Why?
|
Age Factors | 3 | 2019 | 18370 | 0.090 |
Why?
|
Health Services Accessibility | 2 | 2015 | 5137 | 0.080 |
Why?
|
Income | 1 | 2017 | 1913 | 0.080 |
Why?
|
Social Class | 1 | 2017 | 1999 | 0.080 |
Why?
|
Emigrants and Immigrants | 1 | 2015 | 522 | 0.080 |
Why?
|
Pregnancy | 3 | 2022 | 29144 | 0.080 |
Why?
|
Reproducibility of Results | 3 | 2021 | 19905 | 0.070 |
Why?
|
Prevalence | 2 | 2021 | 15226 | 0.070 |
Why?
|
Disease Management | 1 | 2017 | 2459 | 0.070 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 7785 | 0.070 |
Why?
|
Neoplasms | 3 | 2023 | 21683 | 0.070 |
Why?
|
Survival Analysis | 2 | 2011 | 10252 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2017 | 3923 | 0.060 |
Why?
|
Statistics as Topic | 1 | 2011 | 2373 | 0.060 |
Why?
|
Ribavirin | 1 | 2007 | 395 | 0.060 |
Why?
|
Siberia | 1 | 2004 | 32 | 0.060 |
Why?
|
Urban Health | 1 | 2007 | 547 | 0.060 |
Why?
|
Breast Neoplasms | 3 | 2023 | 20822 | 0.060 |
Why?
|
Survival Rate | 1 | 2018 | 12788 | 0.060 |
Why?
|
Aged | 5 | 2022 | 163280 | 0.060 |
Why?
|
United States | 7 | 2023 | 69872 | 0.060 |
Why?
|
Child | 6 | 2021 | 77709 | 0.060 |
Why?
|
Markov Chains | 1 | 2007 | 969 | 0.060 |
Why?
|
Delivery of Health Care | 2 | 2019 | 5319 | 0.060 |
Why?
|
Interferon-alpha | 1 | 2007 | 895 | 0.050 |
Why?
|
Practice Guidelines as Topic | 2 | 2016 | 7279 | 0.050 |
Why?
|
Prisons | 1 | 2004 | 161 | 0.050 |
Why?
|
Research Subjects | 1 | 2004 | 239 | 0.050 |
Why?
|
Decision Support Techniques | 1 | 2011 | 1956 | 0.050 |
Why?
|
Time Factors | 3 | 2020 | 40075 | 0.050 |
Why?
|
Baltimore | 1 | 2021 | 231 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39050 | 0.050 |
Why?
|
Prospective Studies | 2 | 2022 | 53288 | 0.050 |
Why?
|
Artificial Intelligence | 2 | 2023 | 2214 | 0.050 |
Why?
|
Retrospective Studies | 2 | 2019 | 77449 | 0.040 |
Why?
|
Sensitivity and Specificity | 1 | 2015 | 14722 | 0.040 |
Why?
|
Cervix Uteri | 1 | 2023 | 590 | 0.040 |
Why?
|
Recurrence | 1 | 2011 | 8340 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2023 | 13102 | 0.040 |
Why?
|
Vagina | 1 | 2024 | 825 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1873 | 0.040 |
Why?
|
Geography | 1 | 2020 | 669 | 0.040 |
Why?
|
Goals | 1 | 2023 | 706 | 0.040 |
Why?
|
Developed Countries | 1 | 2020 | 437 | 0.040 |
Why?
|
Recombinant Proteins | 1 | 2007 | 6622 | 0.040 |
Why?
|
Occult Blood | 1 | 2017 | 176 | 0.040 |
Why?
|
Standard of Care | 1 | 2020 | 564 | 0.040 |
Why?
|
Sexual Partners | 1 | 2021 | 730 | 0.040 |
Why?
|
Cohort Studies | 2 | 2011 | 40561 | 0.030 |
Why?
|
California | 1 | 2020 | 1402 | 0.030 |
Why?
|
Secondary Prevention | 1 | 2022 | 1530 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15076 | 0.030 |
Why?
|
Risk Assessment | 2 | 2020 | 23338 | 0.030 |
Why?
|
Self Care | 1 | 2020 | 786 | 0.030 |
Why?
|
Cuba | 1 | 2015 | 47 | 0.030 |
Why?
|
Mammography | 2 | 2017 | 2476 | 0.030 |
Why?
|
Publishing | 1 | 2022 | 833 | 0.030 |
Why?
|
Malaria | 1 | 2004 | 1239 | 0.030 |
Why?
|
Florida | 1 | 2015 | 435 | 0.030 |
Why?
|
Cross Protection | 1 | 2012 | 24 | 0.030 |
Why?
|
Community-Based Participatory Research | 1 | 2015 | 214 | 0.030 |
Why?
|
Haiti | 1 | 2015 | 553 | 0.030 |
Why?
|
Algorithms | 2 | 2024 | 13881 | 0.030 |
Why?
|
Homosexuality, Male | 1 | 2019 | 1240 | 0.030 |
Why?
|
Feces | 1 | 2017 | 1401 | 0.030 |
Why?
|
Tuberculosis | 1 | 2004 | 1912 | 0.020 |
Why?
|
Africa South of the Sahara | 1 | 2013 | 724 | 0.020 |
Why?
|
Kenya | 1 | 2012 | 685 | 0.020 |
Why?
|
Biomedical Research | 1 | 2004 | 3309 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2004 | 7913 | 0.020 |
Why?
|
Male | 5 | 2023 | 350118 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2019 | 63114 | 0.020 |
Why?
|
Genotype | 1 | 2020 | 12951 | 0.020 |
Why?
|
Guideline Adherence | 1 | 2015 | 2266 | 0.020 |
Why?
|
Health Behavior | 1 | 2015 | 2636 | 0.010 |
Why?
|
Health Care Costs | 1 | 2015 | 3209 | 0.010 |
Why?
|
Risk Factors | 2 | 2021 | 72290 | 0.010 |
Why?
|
Registries | 1 | 2015 | 8089 | 0.010 |
Why?
|